Selected article for: "immune system and patient recovery"
Author: Petushkova, Anastasiia I.; Zamyatnin, Andrey A.
Title: Papain-Like Proteases as Coronaviral Drug Targets: Current Inhibitors, Opportunities, and Limitations
  • Cord-id: v7u4pvws
  • Document date: 2020_9_28
    • ID: v7u4pvws
    Snippet: Papain-like proteases (PLpro) of coronaviruses (CoVs) support viral reproduction and suppress the immune response of the host, which makes CoV PLpro perspective pharmaceutical targets. Their inhibition could both prevent viral replication and boost the immune system of the host, leading to the speedy recovery of the patient. Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is the third CoV outbreak in the last 20 years. Frequent mutations
    Document: Papain-like proteases (PLpro) of coronaviruses (CoVs) support viral reproduction and suppress the immune response of the host, which makes CoV PLpro perspective pharmaceutical targets. Their inhibition could both prevent viral replication and boost the immune system of the host, leading to the speedy recovery of the patient. Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is the third CoV outbreak in the last 20 years. Frequent mutations of the viral genome likely lead to the emergence of more CoVs. Inhibitors for CoV PLpro can be broad-spectrum and can diminish present and prevent future CoV outbreaks as PLpro from different CoVs have conservative structures. Several inhibitors have been developed to withstand SARS-CoV and Middle East respiratory syndrome CoV (MERS-CoV). This review summarizes the structural features of CoV PLpro, the inhibitors that have been identified over the last 20 years, and the compounds that have the potential to become novel effective therapeutics against CoVs in the near future.

    Search related documents:
    Co phrase search for related documents
    • accessory protein and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • accessory protein and adenosine triphosphate: 1, 2
    • accessory protein structural protein and active site: 1, 2
    • accessory protein structural protein and acute respiratory syndrome: 1, 2, 3, 4
    • accessory protein structural protein and adenosine triphosphate: 1, 2
    • accessory specific and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7
    • active site and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • active site and adenosine triphosphate: 1, 2, 3, 4
    • active site and low binding: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
    • active site and low binding energy: 1, 2, 3, 4, 5, 6
    • active site and low cytotoxicity: 1, 2
    • active site cys and acute respiratory syndrome: 1, 2, 3, 4
    • active site cys and low binding: 1
    • acute respiratory syndrome and adenosine triphosphate: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
    • acute respiratory syndrome and logical approach: 1, 2
    • acute respiratory syndrome and low binding: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory syndrome and low binding energy: 1, 2, 3, 4, 5, 6, 7
    • acute respiratory syndrome and low cytotoxicity: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
    • adenosine triphosphate and low cytotoxicity: 1